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Introduction
This manual summarizes laboratory techniques used in the isolation and
identification of Neisseria meningitidis (the meningococcus), Streptococcus pneumoniae
(the pneumococcus) and Haemophilus influenzae from the cerebrospinal fluid and blood
of patients with clinical meningitis. The procedures described here are not new; most
have been used for many years. Even though they require an array of laboratory
capabilities, these procedures were selected because of their utility, ease of performance,
and ability to give reproducible results. The diversity of laboratory capabilities, the
availability of materials and supplies, and their cost, were taken into account. In addition
to these basic procedures, methods for subtyping and biotyping of these organisms are
included for reference laboratories that have the facilities, the trained personnel, and the
desire to perform them.
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I. Epidemiology of Meningitis Caused by Neisseria meningitidis,
Streptococcus pneumoniae and Haemophilus influenzae  
Bacterial menigitis, an infection of the membranes (meninges) and cerebrospinal
fluid (CSF) surrounding the brain and spinal cord, is a major cause of death and disability
world-wide. Beyond the perinatal period, three organisms, transmitted from person to
person through the exchange of respiratory secretions, are responsible for most cases of
bacterial meningitis: Neisseria meningitidis, Haemophilus influenzae, and Streptococcus
pneumoniae. The etiology of bacterial meningitis varies by age group and region of the
world. Worldwide, without epidemics one million cases of bacterial meningitis are
estimated to occur and 200,000 of these die annually. Case-fatality rates vary with age at
the time of illness and the species of bacterium causing infection, but typically range
from 3 to 19% in developed countries. Higher case-fatality rates (37-60%) have been
reported in developing countries. Up to 54% of survivors are left with disability due to
bacterial meningitis, including deafness, mental retardation, and neurological sequelae.
Two clinically overlapping syndromes – meningitis and bloodstream infection
(meningococcaemia) - are caused by infection with N. meningitidis (meningococcal
disease). While the two syndromes may occur simultaneously, meningitis alone occurs
most frequently. N. meningitidis is classified into serogroups based on the immunological
reactivity of the capsular polysaccharide. Although 13 serogroups have been identified,
the three serogroups A, B and C account for over 90% of meningococcal disease.
Meningococcal disease differs from other leading causes of bacterial meningitis because
of its potential to cause large-scale epidemics. A region of sub-Saharan Africa extending
from Ethiopia in the East to The Gambia in the West and containing fifteen countries and
over 260 million people is known as the “meningitis belt” because of its high endemic
rate of disease with superimposed, periodic, large epidemics caused by serogroup A, and
to a lesser extent, serogroup C. During epidemics, children and young adults are most
commonly affected, with attack rates as high as 1,000/100,000 population, or 100 times
the rate of sporadic disease. The highest rates of endemic or sporadic disease occur in
children less than 2 years of age. In developed countries, endemic disease is generally
caused by serogroups B and C. Epidemics in developed countries are typically caused by
serogroup C although epidemics due to serogroup B have also occurred in Brazil, Chile,
Cuba, Norway and more recently in New Zealand.
Meningitis caused by H. influenzae occurs mostly in children under the age of 5
years, and most cases are caused by organisms with the type b polysaccharide capsule
(H. influenzae type b, Hib). While most children are colonized with a species of
H. influenzae, only 2-15% harbour Hib. The organism is acquired through the respiratory
route.  It adheres to the upper respiratory tract epithelial cells and colonizes the
nasopharynx. Following acquisition of Hib, illness results when the organism is able to
penetrate the respiratory mucosa and enters the blood stream. This is the result of a
combination of factors, and subsequently the organism gains access to the CSF, where
infection is established and inflammation occurs. An essential virulence factor which
plays a major role in determining the invasive potential of an organism is the
polysaccharide capsule of Hib. Meningitis is the most severe form of Hib disease; in most
countries, however more cases and deaths are due to pneumonia than to meningitis.
Meningitis in individuals at the extremes of age infants, young children and the
elderly is commonly caused by S. pneumoniae. Younger adults with anatomic or
functional asplenia, haemoglobinopathies, such as sickle cell disease, or who are
otherwise immunocompromised, also have an increased susceptibility to S. pneumoniae
infection. S. pneumoniae, like Hib, is acquired through the respiratory route. Following
the establishment of nasopharyngeal colonization, illness results once bacteria evade the
mucosal defences, thus accessing the bloodstream, and eventually reaching the meninges
and CSF. As is the case with Hib, many more cases and deaths are due to pneumococcal
pneumonia, even though pneumococcal meningitis is the more severe presentation of
pneumococcal disease.
The risk of secondary cases of meningococcal disease among close contacts (i.e.
household members, day-care centre contacts, or anyone directly exposed to the patient’s
oral secretions) is high. Antimicrobial chemoprophylaxis with a short course of oral
rifampin, a single oral dose of ciprofloxacin, or a single injection of ceftriaxone is
effective in eradicating nasopharyngeal carriage of N. meningitidis. Although very
effective in preventing secondary cases, antimicrobial chemoprophylaxis is not an
effective intervention for altering the course of an outbreak. In epidemics, mass
chemoprophylaxis is not recommended.
Vaccines have an important role in the control and prevention of bacterial
meningitis. Vaccines against N. meningitidis, H. influenzae, and S. pneumoniae are
currently available, but the protection afforded by each vaccine is specific to each
bacterium and restricted to some of the serogroups or serotypes of each bacterium. For
example, vaccines are currently available to prevent H. influenzae infections due to
serotype b (Hib) but not those infections due to other serotypes or unencapsulated
organisms (i.e. nontypeable H. influenzae). In addition to establishing a diagnosis, an
important role for the laboratory, therefore, is to determine the bacteria and
serogroups/serotypes that are causing meningitis in a community.
In industrialized countries, routine use of polysaccharide-protein Hib conjugate
vaccines for immunization of infants has almost eliminated Hib meningitis and other
forms of severe Hib disease. Several studies in developing countries have corroborated
these finding. Pneumococcal polysaccharide vaccines have been used to prevent disease
in the elderly and in persons with chronic illnesses that may impair their natural
immunity to pneumococcal disease. Meningococcal polysaccharide vaccines are
generally used in response to epidemics and for the prevention of disease in overseas
travellers although other uses are currently under investigation.
In addition to the existing armamentarium of vaccines, new generation vaccines
against meningococcal and pneumococcal disease are under development and evaluation.
These vaccines may provide a high degree of protection and broad coverage in all age
groups. Until these vaccines become widely available, the current vaccines should be
used appropriately and efficiently. Use of any of these vaccines will require laboratory
identification of the agents causing disease in addition to epidemiological information
about the age and risk groups that are most affected.
II. General Considerations
This manual provides recommendations for the use of media and reagents in the
isolation and identification of N. meningitidis, S. pneumoniae, and H. influenzae.
Alternatively, other media and reagents not listed in this manual may be substituted
where appropriate. When making changes outside of these recommendations, it may be
helpful for the laboratory staff to consult the authors of this manual.
All of the assays described in this manual should be conducted at Biosafety Level 2.
Please refer to the World Health Organization (WHO) Laboratory Biosafety Manual for
detailed descriptions of safety precautions. 
Antimicrobial susceptibility testing of these organisms is not addressed in this
manual, and readers are referred to special textbooks and manuals (i.e. the Manual of
Clinical Microbiology, the Clinical Microbiology Procedures Handbook, or the WHO
Manual for the National Surveillance of Antimicrobial Resistance of S. pneumoniae and
H. influenzae).
A. Record Keeping
It is recommended that all clinical samples be recorded on a form that provides the
following information:
1. Patient’s name
2. Patient’s age and sex
3. Patient’s hospital room number or address
4. Physician’s name and address or where the physician can be located
5. Anatomical site of specimen collection
6. Date and time of specimen collection
7. Clinical diagnosis and relevant patient history
8. Antimicrobial agents, if any, that the patient is receiving
In addition, each specimen should have a label firmly attached to the specimen
container and bearing the following information:
Patient’s name:_________________________________
Hospital:______________________________________
Room:  _______________________________________   
Physician:  ____________________________________
Specimen type:_________________________________
Date and time of collection:_______________________
Test requested: _________________________________             
A registry at the laboratory should include a bound record book listing each clinical
sample received, specifying the date received, the referring hospital or physician, the
identification of the organism, results of assays performed, and whether the isolate was
sent to the reference laboratory for further studies. In addition, basic information about
the patient should also be noted (age, sex, name, address).
III. Collection and Transport of Clinical Specimens
The collection of clinical specimens is important in the isolation and identification
of bacterial agents that cause meningitis. It is recommended that clinical specimens be
obtained before antimicrobial therapy is begun to avoid loss of viability of the etiological
agents. Treatment of the patient, however, should not be delayed while awaiting
collection of specimens. CSF and blood should be processed in a bacteriology laboratory
as soon as possible.
A. Collection of Cerebrospinal Fluid (CSF)
The collection of CSF is an invasive technique and should be performed by
experienced personnel under aseptic conditions. If meningitis is suspected, CSF is the
best clinical specimen to use for isolating and identifying the etiological agents. The
collection of CSF should be performed for diagnosis only. CSF should be inoculated
directly onto both a supplemented chocolate agar plate (CAP) and a blood agar plate
(BAP).
A1. Lumbar Puncture
Usually, 3 tubes of CSF are collected for chemistry, microbiology, and cytology. If
only one tube of fluid is available, it should be given to the microbiology laboratory. If
more than one tube (1 ml each) is available, the second or third tube should go to the
microbiology laboratory.
The kit for collection of CSF (Figure 1) should contain:
1. skin disinfectant
2. sterile gauze and Band-Aid
3. lumbar puncture needles: 22 gauge/3.5"for adults; 23 gauge/2.5" for children
4. sterile screw-cap tubes
5. syringe and needle
6. transport container
7. Trans-Isolate (T-I) medium (if CSF cannot be analysed in the microbiological
laboratory immediately)
The patient should be kept motionless, either sitting up or laying on the side, with
his or her back arched forward so that the head almost touches the knees during the
procedure (Figure 2). Disinfect the skin along a line drawn between the crests of the two
ilia with 70 % alcohol to clean the surface and remove debris and oils. Then apply
tincture of iodine or povidone-iodine. Let dry. The needle is introduced, and the drops of
fluid (1 ml minimum, 3-4 ml if possible) are collected into sterile, screw-cap tubes. Label
the specimen as described earlier. Do not refrigerate the specimen. Hand carry it
(whenever feasible) to the laboratory as soon as possible. Avoid exposure to excessive
heat or sunlight.
Figure 1. Kit for collection of CSF.
Illustration and procedure reprinted with permission of  J. B. Lippincott Company from
Koneman, Elmer w. et al. (1992). Diagnostic Microbiology, Page 90.
The patient lies on his side with knees flexed and back arched to separate the lumbar
 vertebrae.  The patient is surgically draped, and an area overlying the lumbar spine
 is disinfected.
The space between lumbar vertebrae L3 and L4 is palpated with the sterilely gloved forefinger.
The spinal needle is carefully directed between the spinous processes, through the intraspinous




Figure 2.    Collection of CSF by lumbar puncture.
B. Collection of Blood
For the diagnosis of bacterial meningitis, blood should be collected when a spinal
tap is contraindicated or cannot be performed for technical reasons.
B1. Precautions
Infection may be transmitted from patient to staff and from staff to patient during the
blood-taking procedure. Viral agents are the greatest hazard and in some instances are
potentially lethal. Of particular importance are the viruses causing hepatitis and acquired
immunodeficiency syndrome. To decrease the risk of transmission of these viral agents,
the recommendations below should be followed:
(a) Wear latex or vinyl gloves impermeable to liquids.
(b) Change gloves between patients.
(c) Inoculate blood into blood culture media immediately to prevent the blood from
clotting in the syringe. Syringes and needles should be disposed of in a puncture-
resistant, autoclavable container. No attempt should be made to re-cap the needle. A
new syringe and needle must be used for each patient.
(d) Wipe the surface of the blood culture bottle and the gloves with a disinfectant.
(e) Label the bottle.
(f) For the transport to the microbiology laboratory, place the blood culture medium in a
container that can be securely sealed.
(g) Specimen containers should be individually and conspicuously labelled. Any
containers with blood on the outside should be wiped thoroughly. Such containers
should be transported in individual plastic envelopes.
(h) Remove gloves and discard in an autoclavable container.
(i) Wash hands with soap and water immediately after removing gloves.
(j) Transport the specimen to the microbiology laboratory or, if that facility is closed,
store the specimen in an approved location.
(k) In the event of a needle-stick injury or other skin puncture or wound, wash the
wound liberally with soap and water. Encourage bleeding.
(l) Report any contamination of the hands or body with blood, or any puncture wound
or cut to the supervisor and the health service for treatment.
B2. Sensitivity of Blood Cultures
Several variables affect the sensitivity of blood cultures: the number of collections,
the volume of each collection, and the steps taken to inhibit or neutralize bactericidal
properties of blood may vary with the age of the patient. It may be difficult to collect a
large amount of blood from a child; 1-3 ml is usually sufficient. Blood cultures from
young children should be diluted to 1-2 ml of blood in 20 ml of broth (1:10 to 1:20). Blood cultures from
adults should be diluted to 5-10 ml of blood in 50 ml of broth (1:5 to 1:10).
Blood should be cultured in trypticase soy broth (TSB) or brain heart infusion with a
growth supplement (such as IsoVitaleX or Vitox) to support growth of organisms such as
H. influenzae. Neutralization of normal bactericidal properties of blood and potential
antimicrobial agents is accomplished by adding chemical inhibitors such as 0.025%
sodium polyanetholesulfonate (SPS) to culture media and by diluting the blood. SPS,
which has anticoagulant, antiphagocytic, anticomplementary, and antilysozymal activity,
may be inhibitory if used in higher concentrations.
B3. Venipuncture
An outline of the proper method for collecting blood from the arm is shown in
Figure 3.
(a) Gather everything needed to complete the process: gloves, syringe, needle,
tourniquet, gauze squares, cotton balls, Band-Aid, puncture resistant container,
culture medium and antiseptic; iodine tincture or povidone-iodine is preferred, but
70% alcohol is an acceptable alternative. However, alcohol with concentrations
greater than 70% should not be used because the increased concentrations result in
decreased antibactericidal activity. The size of the needle will depend on the
collection site and the size of the vein. A 23-gauge needle that is 20-25 mm in length
or a butterfly needle is generally used for children.
(b) Select an arm and apply a tourniquet to restrict the flow of venous blood. The large
veins of the forearm are illustrated in Figure 3. The most prominent vein is usually
chosen.
(c) Vigorously wipe the skin with the 70% alcohol, and swab with the iodine tincture or
povidone-iodine. Rub over the selected area. Allow to dry. If the vein is palpated
again, repeat the skin disinfection.
(d) After the disinfectant has dried, insert the needle into the vein with the bevel of the
needle face up. Once the vein is entered, withdraw the blood by pulling back the
barrel of the syringe in a slow, steady manner. Air must not be pumped into a vein.
After the desired amount of blood is obtained, release the tourniquet and place a
sterile cotton ball over the insertion site while holding the needle in place. Withdraw
the needle and have patient hold the cotton-ball firmly in place until the wound has
stopped bleeding. Inoculate the culture medium. Put the Band-Aid on the wound.
(e) Vacutainer tubes should be used for blood collection, if available.
C. Transport of Clinical Specimens
S. pneumoniae, H. influenzae and N. meningitidis are fastidious and fragile bacteria.
They are more reliably isolated if the clinical material is examined as soon as possible
after collection.
C1. CSF
As soon as the CSF has been collected, it should be transported to the microbiology
laboratory, where it should be examined as soon as possible (within one hour from the
time of collection) (Figure 4). Do not expose the CSF to sunlight or extreme heat or cold.
If N. meningitidis is suspected to be the cause of the illness, and a delay of several hours
in processing specimens is anticipated, incubating the CSF (with screw-caps loosened) at
35 •C in a 5% CO
2 atmosphere (or candle-jar) may improve bacterial survival. If same-
day transport to the laboratory is not possible, CSF should be inoculated aseptically into a
Trans-Isolate (T-I) medium with a syringe and held overnight at, or close to, 35 •C. T-I is
a biphasic medium that is useful for the primary culture of meningococci and other
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Figure 3.  Collection of blood from an arm.
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etiological agents of bacterial meningitis from CSF and blood samples (Figure 5). It can
be used as a growth medium as well as a holding and transport medium. The preparation
of the T-I medium is described in Annex C (C4).
(a) The T-I bottle septum should be disinfected with alcohol and iodine and allowed to
dry before inoculation. Inoculate 1 ml of CSF into the T-I medium, which has either
been pre-warmed in the incubator (35 •C-37 •C) or kept at room temperature(25 •C).
Keep the remaining CSF in the container or syringe in which it was collected. Do
not refrigerate, but hold at room temperature before Gram staining.
(b) After inoculation, T-I bottles are incubated at 35 •C overnight. Label the T-I bottle
appropriately with the patient identification, and date and time of CSF inoculation.
Incubate the T-I medium at 35 •C for up to 7 days. Venting the bottle with a venting
needle, or a sterile cotton-plugged hypodermic needle after the initial 24-h
incubation, or as soon as possible after transportation has been completed,
encourages growth and survival. If transport is delayed, vented bottles can be held
for days at moderate to warm room temperatures (25 •C-30 •C). The vents must be
removed before shipment. It is essential to obtain specimens aseptically and to avoid
contamination when inoculating or sampling the bottles.
C2. Blood
(a) Blood cannot be transported before being placed in broth because the collection
procedure does not use an anticoagulant. Blood should be injected into the broth
culture medium within one minute of collection. If the blood culture bottle contains
a diaphragm, clean the diaphragm with 70% alcohol and povidone-iodine before
inoculating the medium. Swirl the bottle several times. Discard the needle and
syringe in a puncture-resistant container. Do not re-cap the needle. Clean the
diaphragm of the blood culture bottle, if necessary. Then label it appropriately with
patient identification and the date and time of blood collection. The preparation of
blood culture media is described in Annex C (C2).
(b) The inoculated medium can be held at room temperature (20 •C-25 •C) for 4 to 6
hours before incubation at 35 •C. Inoculated or uninoculated blood-culture medium
must not be placed in a refrigerator. A portable incubator may be used (temperature
range 25 •C-35 •C).
(c) Immediately transport the inoculated media to the laboratory. All inoculated blood-
culture media should be received by the laboratory within 12 to 18 hours for
subculture and should be protected from temperature extremes (less than 18 •C,
more than 37 •C) with a transport carrier such as Styrofoam, which can keep the
samples at moderate temperature.
     Transport to the   Transport to the
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Figure 4.  Processing of CSF.
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Figure 5.  Trans-Isolate medium.
IV. Primary Culture, Subculture, and Presumptive Identification
A. Inoculation of Primary Culture Media
A1. CSF
Once the CSF has arrived at the microbiology laboratory, centrifuge it for 20
minutes at 2000 rpm. Draw off the supernatant with a Pasteur pipette. When antigen
detection by latex agglutination is planned, save the supernatant. Sediment must be either
vigorously vortexed or well mixed. Use one or two drops of sediment to prepare the
Gram stain and use 1 drop to streak the primary culture media (Figure 4).
Note: If less than 1 ml of CSF is available, do not centrifuge. Use it for the Gram
stain and plate it directly.
The best medium for S. pneumoniae is a BAP, which is a trypticase soy agar (TSA)
plate containing sheep or horse blood (5%). Human blood is not an acceptable substitute.
For H. influenzae, a CAP supplemented with haemin and a growth supplement such as
IsoVitaleX, supplement B, or Vitox should be used. An acceptable alternative to achieve
growth of H. influenzae on BAP is cross-streaking the medium with Staphylococcus
aureus or applying a filter paper/disk saturated with X and V factors to the surface of the
medium, after the medium had been inoculated. H. influenzae forms satellite colonies
along the length of the staphylococcal growth or produces a halo of growth around the
XV strip/disk. N. meningitidis grows on both BAP and CAP, as will S. pneumoniae. If
only one type of plate is available, choose CAP, because all three etiological agents can
grow on it. A bacteriological loop is used to streak or thin the bacteria into single
colonies. BAP that have been properly streaked are shown in Figures 6 and 7, and
properly streaked CAP is shown in Figure 8. The agar plates should be incubated in a 5%
CO
2 incubator or candle-jar. A backup broth (e.g. brain heart infusion broth) should be
inoculated with some of the pellet and also incubated.
When T-I medium was used for transport, after 24 hours of incubation, with a sterile
needle and syringe, transfer 100 µl of the liquid portion of T-I onto BAP and CAP, and
streak for isolation.
1.1. Gram Stain Procedure for CSF (Hucker Modification)
A presumptive diagnosis of bacterial meningitis caused by H. influenzae, S.
pneumoniae, and N. meningitidis can be made by Gram stain of the CSF sediment or by
detection of specific antigens in the CSF by a latex agglutination test. Positive results of
either or both tests can provide evidence of infection, even if cultures fail to grow.
(a) Centrifuge the CSF for 20 minutes at 2000 rpm.
(b) Prepare smear by placing 1 or 2 drops of sediment on an alcohol-rinsed and dried
slide, allowing drop(s) to form one large drop. Do not spread fluid nor use too heavy
a concentration of sediment.
(c) Air dry the slide in a biosafety cabinet, if available.
(d) Pass the slide quickly through a flame three times to fix the smear. Do not flame
until dry. Alternatively, fixation by methanol (95%-100%) can be used.
(e) Flood the smear with ammonium oxalate-crystal violet and let stand for 1 minute.
Figure 6.  N. meningitidis - proper streaking and growth on blood agar plate.
Figure 7.  S. pneumoniae - proper streaking and growth on blood agar plate.
Figure 8.  H. influenzae - proper streaking and growth on chocolate agar plate.
(f) Rinse gently with tap water. Drain off excess water.
(g) Flood the smear with Gram’s iodine solution and let stand for 1 minute.
(h) Rinse gently with tap water and drain.
(i) Decolorize with 95% ethyl alcohol (5-10 seconds may be enough).
(j) Counterstain with safranin for 20-30 seconds, or with carbol-fuchsin for 10-15
seconds.
(k) Rinse the slide with tap water and blot dry.
(l) Examine the stained smear microscopically, using a bright-field condenser and an
oil-immersion lens.
N. meningitidis may occur intra- or extra-cellularly in the polymorphonuclear
leukocytes and will appear as Gram-negative, coffee-bean-shaped diplococci (Figure 9a).
 S. pneumoniae are lanceolate, Gram-positive diplococci sometimes occurring in short
chains (Figure 9b). H. influenzae are small, pleomorphic Gram-negative rods or
coccobacilli with random arrangements (Figure 9c). Other manuals should be consulted
for Gram stain reactions of other bacteria.
1.2. General Method for Performing Latex Agglutination Tests
Several commercial kits are available. Follow the manufacturer’s instructions
precisely when using these tests. General recommendations and instructions typical for
the detection of soluble bacterial antigens are provided here. For best results, test the
supernatant of the centrifuged CSF sample as soon as possible. If immediate testing is not
possible, the sample can be refrigerated (between 2 •C and 8 •C) up to several hours, or
frozen at –20 •C for longer periods. Reagents should be kept refrigerated between 2 •C
and 8 •C when not in use. Product deterioration occurs at higher temperatures, especially
in tropical climates, and test results may become unreliable before the expiration date of
the kit. Latex suspensions should never be frozen.
Performance of the Test
(a) Heat the supernatant of the CSF in a boiling water bath for 5 minutes.
(b) Shake the latex suspension gently until homogenous.
(c) Place one drop of each latex suspension on a ringed glass slide or a disposable card.
(d) Add 30-50 µl of the CSF to each suspension.
(e) Rotate by hand for 2-10 minutes. Mechanical rotation at 100 rpm, if available, is
recommended.
Reading the Test Results
Read under a bright light without magnification.
Negative reaction: the suspension remains homogenous and slightly milky in
appearance.
Positive reaction: agglutination (or visible clumping) of the latex particles occurs within
2 minutes,.
Note: Counter immunoelectrophoresis may also be used for direct antigen detection
in CSF.
A2. Blood
The blood culture bottles are inoculated directly with blood and should be vented
before incubation at 35 •C-37 •C. This is accomplished by inserting a sterile cotton-
plugged needle into the rubber part of the blood culture bottle.
B. Subculture
Since the primary purpose of this manual is to aid in the identification of
N. meningitidis, S. pneumoniae, and H. influenzae, the methods described here will not
allow for identifying other isolates that may be of clinical importance but more rarely
encountered. Microbiologists should refer to clinical microbiology manuals, such as the
American Society for Microbiology’s Manual of Clinical Microbiology, for procedures to
identify other bacteria.
B1. Blood Culture Bottle
Examine the blood culture bottles at 14 to 17 hours and then every day for up to 7
days. Any turbidity or lysis of the erythrocytes may be indicative of growth, and
subcultures should be made immediately. Since these three organisms are fragile,
subcultures should be performed after 14 to 17 hours of incubation, again at 48 hours,
and at day 7, regardless of the appearance of the blood culture bottles, since the
absence of turbidity does not always correlate with the absence of bacterial growth.
Before subculturing, swirl the bottle to mix the contents.
Subcultures are made by first disinfecting the surface of the blood culture bottle
rubber stopper with alcohol and a povidone-iodine swab, and then aspirating a small
volume (0.5 ml) with a syringe and needle from the blood culture bottle and inoculating
the agar media with the fluid. Ordinarily, both CAP and BAP are used for subculture.
When only one agar plate is used, it should be CAP, since CAP contains growth factors
needed for H. influenzae whereas BAP does not. The agar plates should be streaked as
shown in Figures 6, 7 and 8, and incubated for up to 48 hours. When bacterial growth has
been confirmed by subculture of the blood culture bottle, there is no need to continue to
incubate the bottle. The bottle should be disposed of according to safety procedures.
B2. T-I Medium
(a) After 24 hours of incubation, using a sterile needle and syringe, transfer 100 µl of the
liquid portion of T-I onto BAP and CAP, streak the plate, and incubate at 35 • C in a
CO
2 atmosphere for up to 48 hours.
(b) Check for purity of the growth by performing Gram stain.
(c) If no growth occurs, subculture the T-I medium at 3 days and again at 7 days.
C. Macroscopic Examination of Colonies
N. meningitidis grows on BAP, but H. influenzae does not. When grown on CAP, H.
influenzae and N. meningitidis look similar, but the two can be distinguished: H.
influenzae gives off a pungent smell of indol, while N. meningitidis does not.
Figure 9a.  Gram  stain of cerebrospinal fluid: N. meningitidis: intra-cellular, gram-negative diplococci.
Figure 9b.  Gram stain of cerebrospinal fluid: S. pneumoniae: gram-positive diplococci. Note that this
       slide represents a case where an exceptionally large number of organisms are present.
Figure 9c.  Gram stain of cerebrospinal fluid: H. influenzae: gram-negative pleomorphic coccobacilli.
Moreover, H. influenzae appears as large, flat, colorless-to-grey opaque colonies
(Figure 10). No haemolysis or discoloration of the medium is apparent.
On BAP, young colonies of N. meningitidis are round, smooth, moist, glistening and
convex, with an entire edge. Some colonies appear to coalesce with their neighbours.
Growth is greyish and unpigmented. Older cultures become more opaquely grey and
sometimes cause the underlying agar to turn dark. Well-separated colonies can grow from
about 1 mm in diameter in 18 hours to as large as 4 mm, with a somewhat undulating
edge, after several days (Figure 11).
S. pneumoniae appears as small, greyish, moist (sometimes mucoid), watery
colonies with a greenish zone of alpha-haemolysis surrounding them on BAP (Figure 12)
and CAP. Young pneumococcal colonies appear raised, similar to viridans streptococci.
However, once the culture ages 24 hours to 48 hours, the colony becomes flattened, and
the central portion becomes depressed. Thus, a microscope (30x-50x) or a 3x hand lens
can be a useful tool in differentiating pneumococci from alpha-haemolytic viridans
streptococci. Presumptive identification can be made on the basis of the growth on BAP
and CAP, and on the basis of the microscopic morphology of the organisms (Figures 13
and 14).
Figure 10.  On chocolate agar plate, H. influenzae appear as large colorless to gray, opaque
          colonies with no discoloration of the surrounding medium.
Figure 11.  Overnight growth of N. meningitidis on blood agar plate appears as round, moist,
         glistening and convex colonies.
Figure 12.  S.  pneumoniae appear as small grayish mucoid (watery) colonies with a greenish zone of
         alpha-hemolysis surrounding them on the blood agar plate.
Figure 13.  Presumptive identification of N. meningitidis, S. pneumoniae, and H. influenzae.
   Growth on Gram stain Presumptive
identification    CAP           BAP
         (Sheep)
        +           Gram-negative H. influenzae
pleomorphic
coccobacilli
     +  + Gram-negative N. meningitidis
diplococci
       +          + Gram-positive S. pneumoniae
diplococci
Figure 14.  N. meningitidis (left), S. pneumoniae (right), and  H. influenzae (top):
       (a)  growth on blood agar plate and (b) growth on chocolate agar plate.
(a) Growth on  blood agar plate.
(b) Growth on  chocolate agar plate.
V. Identification of N. meningitidis
The following steps are recommended to confirm the identity of cultures that
morphologically appear to be N. meningitidis (Figure 15). The best results are obtained
with day-old cultures. Always check for purity of the growth by performing a Gram stain
(N. meningitidis is a Gram-negative, coffee-bean-shaped diplococcus). When necessary,
make subcultures to ensure purity. From growth on a BAP, perform Kovac’s oxidase test,
and then identify the serogroup. Finally, confirm the results with carbohydrate (sugar)
reactions.
A. Kovac’s Oxidase Test
The oxidase test determines the presence of cytochrome oxidase. The reagent
tetramethyl-p-phenylenediamine hydrochloride is turned into a purple compound by
organisms containing cytochrome c as part of their respiratory chain.
Preparation of 1% Oxidase Reagent from Powder
To prevent deterioration of stock oxidase-reagent powder, store in a tightly closed
bottle in a desiccator kept in a cool dark area. Prepare 10 ml of a 1.0% tetramethyl-p-
phenylenediamine hydrochloride solution in distilled water. Dispense the reagent in 1-ml
aliquots and store frozen at –20 •C. For use, thaw a 1-ml vial and wet as many strips of
filter paper as possible on a nonporous surface (i.e. Petri dish, glass plate). Let the strips
dry in air. When the strips are completely dry, place them in a tightly capped tube/bottle
and refrigerate at 4 •C. Use as needed.
Note: Oxidase reagent is intended only for in vitro diagnostic use. Avoid contact
with the eyes and skin. It can cause irritation. In case of contact, immediately flush eyes
or skin with plenty of water for at least 15 minutes.
Performance of the Test
Using a platinum inoculating loop, a disposable plastic loop, or a wooden applicator
stick, pick a portion of the colony to be tested and rub it onto a treated strip of filter paper
(Figure 16). Do not use a Nichrome loop, since it may produce a false-positive reaction.
Reading Test Results
Positive reactions will develop within 10 seconds in the form of a purple colour.
Delayed reactions are unlikely with N. meningitidis. This test aids in the recognition of N.
meningitidis, but other members of the genus Neisseria, as well as unrelated bacterial
species, may also give a positive reaction.
B. Identification of the N. meningitidis Serogroup
Twelve serogroups, based on capsular polysaccharides, are currently recognized: A,
B, C, H, I, K, L, W135, X, Y, Z, and Z’ (29E).
Note: serogroup D is no longer recognized.
Figure 15.  Identification of N. meningitidis.
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Figure 16.  Kovac’s oxidase test - positive reaction.
Groups A, B, C, W135 and Y are the most common causes of meningitis. Serogroup
A is the most common cause of epidemics in Africa and Asia, followed by serogroup C.
Grouping antisera are available commercially.
Performance of the Test
(a) Clean a glass slide with alcohol. Divide the slide into three 10x4-mm sections with a
wax pencil or other marker.
(b) Place 10 µl of 0.5% formalinized saline near the bottom of each of three sections.
Collect a portion of the growth from the surface of the BAP with a sterile
inoculating loop, needle, sterile applicator stick or toothpick. Make a moderately
milky suspension of the culture being tested in each drop of saline.
Note: For safety reasons, it is recommended to use formalin-killed meningococcal
suspensions rather than saline suspensions of living organisms. However, formalin
is a carcinogen and must be stored and handled with great care. Alternatively, work
under a safety hood.
(c) In the upper portion of each glass section, add 10 µl each of the antiserum of choice
and saline/phosphate-buffered saline (PBS) (unformalinized).
Note: In Africa, testing with A and C antisera with a saline control to detect
nonspecific autoagglutination should be adequate to characterize most isolates
serologically. Strains reacting negatively with A and C antisera should then be
tested with other available antisera, particularly Y, W135 and B.
(d) Mix each antiserum and saline with the respective culture suspension and rock the
slide for 1 to 2 minutes (time may vary depending on the manufacturer of the
antisera) under a bright light and over a black background.
Reading the Test Results
Agglutination should occur with only one of the antisera and not with saline
(Figure 17). Agglutination in saline would characterize the culture as autoagglutinable.
Agglutination with several serum samples in the absence of agglutination in saline would
characterize the culture as rough. No agglutination with any of the antisera or the saline
would characterize the strain as non-groupable. These results are rare with fresh case
isolates, but they do happen occasionally. Store antisera and saline/PBS in the refrigerator
at 4 •C when not in use.
C. Carbohydrate Utilization by N. meningitidis - Cystine Trypticase Agar Method
Carbohydrate utilization tests are used to further validate the identification of a
strain as N. meningitidis. Various carbohydrates are added to the cystine trypticase agar
base to a final concentration of 1%. To confirm a culture as N. meningitidis, a set of four
tubes, each containing a sugar (glucose, maltose, lactose, and sucrose) is used. Members
of Neisseria spp. produce acid from carbohydrates by oxidation, not fermentation. N.
meningitidis oxidizes glucose and maltose, but not lactose and sucrose. A phenol red
indicator is included in the medium; it is a sensitive indicator that develops a yellow
colour in the presence of acid, at a pH of 6.8 or less.
Performance of the Test
Figure 17.  Agglutination, with clearing of the liquid, occurs when a suspension of
        the isolate is mixed with its homologous antiserum (left). A negative
        reaction, which should occur with heterologous antiserum (center) and
        with saline (right), remains smooth and turbid.
(a) With an inoculating needle, take up a small amount of growth from an overnight
culture on BAP or CAP.
(b) Stab the inoculum several times into the upper 10 mm of medium. Use a separate
needle, or flame the needle, before inoculating each carbohydrate to be tested.
(c) Fasten caps of tubes tightly and place in a 35 •C incubator (without CO2). Incubate
for at least 72 hours before discarding as negative.
Reading the Test Results
Development of visible turbidity and a yellow colour in the upper portion of the
medium indicates growth and the production of acid and is interpreted as a positive test
(Figure 18). Although reactions may occur as early as 24 hours after inoculation, some
reactions are delayed, and negative results should not be interpreted before 72 hours of
incubation (Table 1).
D. Commercial Identification Kits
Several commercial identification systems that use biochemical or enzymatic
substrates are available for identification of Neisseria spp. These systems may
occasionally require supplemental tests, and additional characteristics, such as
microscopic and colony morphology, must be considered. Generally, each system is self-
contained, but addition of one or more reagents to complete certain reactions may be
necessary. Follow the manufacturer’s instructions precisely when using these kits. For
detailed instructions and use of appropriate control strains also consult the Clinical
Microbiology Procedures Handbook. Alternatively, the rapid sugar utilization tests may
be used.
Figure 18.  Cystine trypticase agar-sugar reactions differentiating N. meningitidis from other Neisseria
       species. Acid production (yellow color) shows oxidative utilization of dextrose and
       maltose with no utilization of lactose and sucrose.
Table 1: Carbohydrate Utilization by Some Species 
of the Genus Neisseria and Moraxella
Acid Production from:
Species Glucose Maltose Lactose Sucrose
Neisseria meningitidis + + - -
Neisseria gonorrhoeae + - - -
Neisseria sicca + + - +
Neisseria lactamica + + + -
Moraxella catarrhalis - - - -
VI. Identification of S. pneumoniae
S. pneumoniae appear as small, greyish, mucoid (watery) colonies surrounded by a
greenish zone of alpha-haemolysis on BAP and CAP. A 3x hand lens or a microscope
(30x-50x) is a useful aid in differentiating pneumococci from alpha-haemolytic viridans
streptococci. Both types of colonies appear raised when young. However, after 24-48
hours, the centre of pneumococcal colonies becomes depressed whereas viridans
streptococcalcolonies retain their raised appearance. Differentiation between S.
pneumoniae and viridans streptococci is accomplished by optochin and bile solubility
testing (Figure19). For optimal results it is recommended that plates for all assays be
incubated in a CO
2 atmosphere.
A. Susceptibility to Optochin
Presumptive identification of S. pneumoniae is made by determining the
susceptibility of the strain to optochin.
Performance of the Test
(a) Touch the suspect alpha-haemolytic colony with a sterile bacteriological loop and
streak onto a BAP, as shown in Figure 7.
(b) Aseptically place an optochin or “p” disk with a diameter of 6 mm (containing 5 µg 
ethylhydrocupreine) on the end of the streak where the wire loop was first placed.
Three to four colonies may be tested on the same plate.
(c) Incubate the plates in a CO
2 incubator or candle-jar at 35 •C for 18-24 hours.
Reading the Test Results
In Figure 20, the strain in the top streak is resistant to optochin and, therefore, is not
a pneumococcus. The strains in the centre and lower streaks are susceptible to optochin
and appear to be pneumococci. Alpha-haemolytic strains with a zone of inhibition of
growth greater than 14 mm in diameter are pneumococci. Alpha-haemolytic strains with
no zones of inhibition are viridans streptococci. Alpha-haemolytic strains with zones of
inhibition ranging between 9 and 13 mm should be tested for bile solubility.
B. Bile Solubility Test
Performance of the Tests
(a) Take a loop of the strain from the growth on a BAP and make a suspension in 0.5 ml
of sterile saline. If there is sufficient growth on the optochin test plate, the
suspension can be made with the cells taken from the single streak. When there is
insufficient growth to make a satisfactory suspension, a fresh culture on blood agar
will have to be made. The suspension of cells should be equal to that of a 0.5
McFarland density standard (Annex C5).
(b) Divide the suspension into two equal amounts (0.25 ml per tube), and add 0.25 ml
of saline to one tube and 0.25 ml of 2% deoxycholate (bile salts) to the other. Shake
the tubes gently and incubate them at 35 •C-37 •C for up to 2 hours.
(c) Examine the tubes periodically for lysis of cells in the tube containing the bile salts.
A clearing of the tube, or a loss in turbidity, as shown in Figure 21, is a positive
result.
Alternatively, in a plate method for testing bile solubility, a drop of solution of 10%
sodium deoxycholate is placed directly on a colony of the strain to be tested. The plate
can be kept at room temperature or placed right side up and on a level surface in an
aerobic incubator at 35 °C for approximately 15 minutes or until reagent dries.
Pneumococcal colonies will disappear or be flattened, while bile-resistant streptococcal
colonies will be unaffected. It is essential to use a freshly prepared plate for this test.
Interpreting the Test Results
Usually, the most accurate and convenient identification of pneumococci, based on
the optochin and bile solubility tests, is the following:
(a) A strain showing a zone of inhibition by optochin of 14 mm or more is a
pneumococcus.
(b) A strain showing a smaller but definite zone of inhibition by optochin and is bile
soluble is also a pneumococcus.
(c) A strain with a small zone of inhibition by optochin that is not bile soluble is not a
pneumococcus.
(d) Strains with no zones of inhibition by optochin are not pneumococci (Figure 19).
C. Slide Agglutination Test
Commercially available slide agglutination tests can help identify colony growth
from BAP as pneumococci (e.g. Slidex Pneumo [Vitek Systems, Inc., Hazelwood, MO]
or Pneumoslide [BBL Microbiology Systems, Cockeysville, MD]). Follow the
manufacturer’s instructions precisely when using these tests.
Alternatively, in a plate method for testing bile solubility, a drop of solution of 10%
sodium deoxycholate is placed directly on a colony of the strain to be tested. The plate
can be kept at room temperature or placed right side up and on a level surface in an
aerobic incubator at 35 °C for approximately 15 minutes or until the reagent dries.
Pneumococcal colonies will disappear or be flattened, while bile-resistant streptococcal
colonies will be unaffected. It is essential to use a freshly prepared plate for this test.
Figure 19.  Identification of S. pneumoniae.
Growth on CAP
 Growth on BAP







            ZI  > 14*
14 >ZI > 8











Note: ZI = Zone of inhibition for BBL optochin disks. When using any other brand of optochin disks,
follow the instructions for the interpretation of zones of inhibition, as specified by that manufacturer.
*95% of clinical S. pneumoniae isolates react in this manner
-
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Figure 20.  Optochin susceptibility test for identification of S. pneumoniae. The strain in
         the top streak is resistant to optochin and, therefore, is not a pneumococcus.
                       The strains in the center and lower streaks are susceptible to optochin and
                    appear to be pneumococci.
Figure 21.  The bile solubility test for two different strains. Strain 1 is not S. pneumoniae as both
       tubes are turbid. There is a slight decrease in turbidity in the tube containing bile salts
       for strain 1 (2nd tube from the left) but the tube is almost as turbid as the control tube
       (1st tube on the left).  Strain 2 is S. pneumoniae.  Note that the tube on the far right is
       clear, all the turbidity due to the cells has disappeared and the cells have lysed; by
       contrast the control tube (3rd tube from the left) is still very turbid.
VII. Identification of H. influenzae
Small, Gram-negative bacilli or coccobacilli which require X and V factors, grow on
CAP and not on BAP, have a pungent indol smell, and do not group with meningococcal
antisera, may be H. influenzae (Figure 22). In the absence of vaccination, almost all cases
of meningitis caused by H. influenzae are serotype b.
A. Identification of the H. influenzae Serotype
Performance of the test is similar to that described for N. meningitidis except for the
choice of antisera. Suspected Hib isolates should be tested against H. influenzae type b
antiserum, an antiserum to one of the other groups, and saline. A strongly positive
reaction with b antiserum and no reactivity with an antiserum to one of the other groups
and saline is presumptive evidence of Hib. If the isolate is non-reactive with the b
antiserum, test it with a polyvalent antiserum. If positive, the isolate must be tested with
there maining antisera (a, c, d, e, f) to determine its serotype. If negative, it is probably
non-typable. Determination of X and V factor requirements is necessary to confirm the
identity of the isolate as H. influenzae or another Haemophilus species.
Performance of the Test
(a) Make a milky suspension of cells from an overnight culture on the CAP or the
Haemophilus ID plate in 10 µl of 0.5% formalinized saline.
(b) For the agglutination reaction, transfer a loopful (5 µl) of the cell suspension to an
ethanol-washed slide divided into three sections.
(c) To each section, respectively, add an equal volume of Hib antiserum, a different
type specific antiserum, and saline.
(d) Mix with a toothpick and gently rock the slide for up to a minute.
Reading of Test Results
Only strong agglutination reactions are read as positive. In a strong reaction, all the
bacterial cells will be clumped and the suspension fluid will appear clear. When a strain
reacts with more than one antiserum, the result is recorded as non-typable.
Note: Haemophilus can also be serotyped by using the Quellung reaction, as
described for the serotyping of S. pneumoniae (Annex D).
B. Identification of X and V Factor Requirements
B1. X, V and XV Paper Disks and Strips
H. influenzae is a fastidious organism requiring media containing haemin (X factor)
and nicotinamide adenine dinucleotide (NAD, V factor). Growth occurs on CAP because
of haemin released during the heating process in the preparation of chocolate agar.
Haemin is available from non-haemolyzed as well as haemolyzed cells. Alternatively,
NAD is added as an IsoVitalex or Vitox component. H. influenzae is identified on the
basis of its growth requirements for X and V factors (Table 2).
Figure 22.  Identification of H. influenzae.
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Gram stain: gram-negative pleomorphic coccobacilli
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Performance of the Test
(a) Prepare a heavy suspension of cells (No. 1 McFarland) from a primary isolation
plate in a suitable broth (trypticase soy, heart infusion, or peptone water). If the
primary isolation plate contains insufficient growth or is contaminated, make a
subculture on a CAP. Caution should be used in preparation of the broth to avoid
transfer of media to the broth; even the smallest sample of agar will affect the test
and may lead to misidentification of the bacteria.
(b) Inoculate a heart infusion or tryptic soy agar plate. A sterile swab of the suspension
is streaked over one-half of the plate, and paper strips or disks containing X, V, and
XV factors are placed on the inoculated plate after the inoculum has dried. When
two bacterial strains are tested on the same plate, as shown in Figure 23, the disks
must be placed in the exact manner shown.
Reading the Test Results
H. influenzae will grow only around the disk containing both X and V factors, as
shown in Figure 23 on the upper half of the plate.
Alternatively, the porphyrin test of Kilian can be used. This determines the
X-factor requirement of the isolate while avoiding the problem of X-factor carryover
from primary culture media and X-factor contamination of test media (Manual of Clinical
Microbiology).
B2. Haemophilus ID “Quad” Plates
These plates are another, although more expensive, method for determining factor
requirements of Haemophilus isolates (Figure 24). This agar plate is divided into four
compartments. One quadrant includes medium containing haemin (X factor) (upper left).
One quadrant includes medium containing NAD (V factor) (lower left). Another quadrant
contains medium that includes both X and V factors (upper right). The fourth quadrant
contains heart infusion agar or blood agar base with 5% horse blood (lower right) for
differentiating
H. haemolyticus, an oral species requiring X and V factors, from H. influenzae.   
Performance of the Test
(a) Inoculate the Haemophilus ID plate by suspending the growth from a young, pure
culture of suspected Haemophilus in TSB or distilled water to approximately the
turbidity of 0.5 McFarland standard. Using a bacteriological loop, streak one loopful
of this suspension on each quadrant of the plate, beginning with the V quadrant and
ending with the blood quadrant. Streak the entire quadrant, starting at the periphery
and streaking toward the centre of the plate. Stab into the blood agar for detection of
weak haemolysis.
(b) Incubate at 35 •C in a candle-jar or CO
2 incubator for 18-24 hours.
Figure 23.  Growth factor  requirements.  H. influenzae will grow only around the disk
           containing  both  X and V factors.
Figure 24.  Growth factor requirements for H. influenzae:  Haemophilus quad  ID plate. This agar plate
          is divided into four compartments.  One quadrant includes medium containing
          haemin (X factor) (upper left). One quadrant includes medium containing
         nicotinamide dinucleotide (V factor) (lower left). Another quadrant contains
         medium that includes both X and V factors (upper right).  The fourth quadrant
         contains heart infusion agar with 5% horse blood (lower right).
Table 2:  Identification of Haemophilus Species by their Growth Requirements
Species  X- and V- Factor Requirements $-haemolysis on Rabbit
Blood AgarX V
H. influenzae + + -
H. parainfluenzae - + -
H. haemolyticus + + +
H. parahaemolyticus - + +
H. aphrophilus + - -
H. paraphrophilus* - + -
*H. paraphrophilus is ornithine negative, whereas H. parainfluenzae is positive.
Reading the Test Results
After incubation, examine the blood section for haemolysis and the other sections
for growth (Figure 24). An organism growing on both the V and X quadrant requires
neither, and thus is not a Haemophilus. Very light background growth on the V section
may be seen with some X- and V-requiring Haemophilus strains. This should be
disregarded.
VIII. Preservation and Transport of N. meningitidis, S. pneumoniae and
H. influenzae
To confirm the identification and to test antimicrobial susceptibility of bacteria
isolated from cases of meningitis, it may be necessary to preserve and transport the
strains to national, and/or WHO Reference Laboratories. N. meningitidis, S. pneumoniae
and H. influenzae are fragile bacteria, and care must be employed to preserve and
transport them.
A. Short-Term Storage
Viability during short-term storage (one week or less) is best if S. pneumoniae and H. influenzae are
inoculated onto chocolate agar slants (with screw-capped tubes), incubated overnight at 35 •C, and then
maintained at 4 •C. These bacterial species do not survive well in broth and survive only 3-4 days on
primary agar plates. For N. meningitidis, solid screw-caps should be loosened during storage but
permeable membrane screw-caps, which allow for an exchange of gases and are available commercially
(Biomedical Polymers, Leominster, MA) should be used. An overlay of TSB may also be helpful, and
may increase viability to 14 days. N. meningitidis slants should not be refrigerated.
B. Long-Term Storage
Long-term storage is best accomplished by either lyophilization or freezing.
Lyophilization is the most convenient method of storage because lyophilized bacteria can
be stored for long periods at 4 •C or –20 •C and should not be adversely affected by
transport.
B1. Preservation by Lyophilization
(a) Grow the H. influenzae on CAP and the S. pneumoniae and N. meningitidis on BAP
or CAP. Incubate the plates in a CO
2 incubator or candle-jar for 18-20 hours at
35 •C. Inspect the plate for purity.
(b) Harvest the growth from the plate with l-2 ml of sterile skim milk. Place about 0.5
ml of suspension into a sterile ampoule or lyophilization vial. Several vials can be
prepared from a single plate, if desired. Maintain sterility at all times during the
preparation of the vial.
(c) The cell suspension should be shell-frozen on the walls of the lyophilization vial.
This is accomplished by one of two methods. Keep the lyophilization vial at –70 •C
until just before the cell suspension is added. Add the cell suspension, and rapidly
rotate the vial to freeze the suspension to the wall. Return the vial to the – 70 •C
freezer until ready to attach to the lyophilizer. If a –70 •C freezer is not available, a
mixture of alcohol (95% ethanol) and dry ice can be prepared and used to shell-
freeze the cell suspensions. Shell-freezing is accomplished by placing the cell
suspension in the lyophilization vial and rotating the vial at a 45o to 60o angle in the
alcohol-dry ice mixture.
(d) Attach the vials to the lyophilizer. Follow the manufacturer’s instructions since each
instrument uses different types of apparatus. The time of lyophilization will depend
upon the number of vials being lyophilized and the capacity of the instrument. On
an average machine, 4-5 hours are required to completely dry 10 to 20 small vials.
(e) The vials are sealed at the end of the run. Seal the vials with a torch while they are
still attached to the lyophilizer and under vacuum. The vials can be stored at 4 •C or
at freezer temperatures after being sealed.
B2. Preservation by Freezing
(a) Grow the H. influenzae on CAP and the S. pneumoniae and N. meningitidis on BAP
or CAP. Incubate the plates in a CO
2 incubator or candle-jar for 18-20 hours at
35 •C. Inspect the plates for purity.
(b) Harvest all of the growth from a plate with a sterile swab.
(c) Dispense the growth in a 2-ml screw-capped (externally threaded) cryogenic vial,
containing 1 ml of sterile defibrinated blood, by twirling the swab to release the
organisms. Defibrinated sheep, horse, or rabbit blood can be used for all of these
organisms. Human blood should not be used. Alternatives such as TSB with 15%-
20% reagent grade glycerol, or Greaves solution can also be used. The vials should
be cryogenic (able to withstand extreme cold).
(d) Squeeze the excess blood from the swab by rotating it against the sides of the vial
before carefully withdrawing it.
(e) Discard the swab in disinfectant.
(f) If possible, rapidly freeze the suspension in a bath of 95% alcohol and dry-ice
pellets.
(g) Place the vials in a nitrogen freezer (-120 •C) or a –70 •C freezer. A –20 •C freezer
can be used, but some loss of viability can be expected. Freezers with automatic
defrosters should never be used.
C. Transportation of Cultures
Lyophilized cultures and chocolate agar slant cultures can be transported without
refrigeration. The cultures should be packaged according to the regulations specified in
the WHO Laboratory Biosafety Manual. Each vial or tube should be individually
wrapped before being enclosed in a metal container including absorbent material. This
container is then inclosed in a cardboard shipping container. An address label and an
etiological agent-warning label (EA label) are attached to the shipping container. No
more than 50 ml of culture should be shipped in one package.
Individually wrapped, lyophilized culture vials can be transported in double-mailing
containers. Cultures stored in the frozen state must be recultured, inoculated onto
chocolate agar slants in screw-capped tubes, incubated overnight, and then packaged for
transport as indicated above. H. influenzae, N. meningitidis, and S. pneumoniae will
usually survive for at least a week under these conditions.
C1. Transport in Silica Gel Packages
N. meningitidis, S. pneumoniae and H. influenzae can be successfully transported in
silica gel packages, which are easy to handle and ship (Figure 25).
Figure 25.  Instructions for using  silica gel envelopes for transport of isolates.
growth
(a) Grow the bacteria on BAP or CAP (H. influenzae). Incubate the plates in a CO2 or
candle-jar for 18-20 hours at 35 •C. Inspect the plate for purity.
(b) Harvest all of the growth from a plate with a sterile swab.
(c) Cut open the silica gel package and place the swab in it. Fold the corners and seal
the silica gel package with the tape. Label the silica gel package with the appropriate
identification number.
(d) When the swabs in silica gel packages are kept at 4 •C, N. meningitidis can survive
at least 3 weeks, and S. pneumoniae and H. influenzae at least 2 weeks. At room
temp-erature, N. meningitidis, H. influenzae, and S. pneumoniae can survive 2
weeks.
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X. Annexes
Annex A. Basic Requirements, Supplies and Equipment






gas supply for burners
bench space (4-6 ft/person)
distilled water supply
desk lamps




sharp disposal box (needles)






























Bunsen or alcohol burners





A2. Table 4: Equipment and Supplies Needed for Collection of Clinical Specimens
and Isolation and Identification of  N. meningitidis, S. pneumoniae
and H. influenzae
Procedure Supplies Equipment





adult spinal needle 22 gauge 3.5"





tincture of iodine or povidone-iodine
swabs










































Bunsen or alcohol burners














containers for autoclave autoclave
8. 
Identification 

















   (oil immersion)





vials or ampoules -70 °C or N2 freezer








Erlenmeyer flasks (250 ml, 500 ml, 1 l, 2 l)









cylinders (50 ml, 100 ml, 250 ml, 500 ml,








Annex B. Media and Reagents
Note : The following list of the manufacturers of the commonly used media and reagents
does not indicate special endorsement of these products and/or manufacturers by WHO.
Please follow closely the manufacturer’s instructions when using these media and
reagents.
B1. Table 5: Media and Reagents Necessary for Isolation and Identification of  N. meningitidis, S. pneumoniae and H. influenzae*
Reagents/ Media BD CSM Sigma Difco BBL Oxoid bioMérieux Sanofi Pasteur Unit
Blood agar base 51 431 64524 500 g
Trypticase soy agar 4311043 0369-17-6 11043 CM131B 51 461 64554 500 g
Trypticase soy agarψ 4321283 2071-30-0 21283 100 plates
Trypticase soy agar with











43 321 63825 20 plates
100 plates
Mueller-Hinton agar 4311438 0252-17-6 11438 CM337B 64884 500 g








Trypticase soy broth 4311768 T8907 0370-17-3 11768 CM129B 51 141 64144 500 g
Trypticase soy broth
with SPS & CO2ψ
1712-37-4 21480 10 x 50 ml
Heart infusion broth 99532 0038-17-7 500 g
Heart infusion agar 12435 0044-17-9 500 g
Mueller-Hinton broth 11443 0757-17-6 11443 CM405B 69444 500 g
Reagents/ Media BD CSM Sigma Difco BBL Oxoid bioMérieux Sanofi Pasteur Unit
Trypticase soy brothψ 4321716 21716 100 x 5 ml
GC agar 4311275 0289-17-3 11275 CM367B 500 g
Chocolate agar platesψ 4321169 21169 43 101 63934 20 plates
100 plates
Chocolate agar slantsψ 4321348 21348 10 slants
Haemoglobin, dried
bovine 
11871 11871 LP053B 100 g
Haemoglobin (2% sol)ψ 11874 3248-73-8 B11874 10 x 100 ml























Crystal violetψ 12293 12293 55 545 4 x 250 ml
Iodineψ 12294 12294 55 546 4 x 250 ml
Acetone-alcoholψ 12295 12295 55 547 4 x 250 ml




1 N sulfuric acid 84728












Reagents/ Media BD CSM Sigma Difco BBL Oxoid bioMérieux Sanofi Pasteur Unit












V-factor disksψ 31108 1694-90-0 DD004A 50 discs
X-factor disksψ 31006 1695-90-9 DD003A 50 discs
XV-factor disksψ 31104 1696-90-8 DD005A 50 discs
Haemophilus quad ID 4397890




Reagents/ Media BD CSM Sigma Difco BBL Oxoid bioMérieux Sanofi Pasteur Unit
T-I medium
  -supplement B
  -activated charcoal
  -soluble starch
  -agar
  -trypticase soy           
  broth
  -gelatin
  -3 LN- morpholino    
    propanesulfonic       


















*BD - Becton Dickinson and Co., CSM - Carr-Scarborough Microbiologicals, Inc., Sigma - Sigma Chemical Co., Difco - Difco Laboratories, BBL -
BBL Microbiology Systems. For the manufacturers’ addresses and contact numbers, please see section B4.
ψ Although commercially prepared media and reagents are more expensive than media or reagents that can be prepared locally, there will be times when
commercially available items will be preferable.  It may be desirable to purchase the supply of media and reagents to perform short-term studies rather
than attempt formulation.  The media and reagents designated with (ψ) are available in ready-to-use form in most parts of the world.  It is essential that
each medium lot have a satisfactory expiry date and that this date and lot number be recorded in the laboratory, and noted for quality and control testing.
 
B2. Table 6: Commercially Available Tests for Latex Agglutination, Co-Agglutination and Serogrouping/Serotyping 
of  N. meningitidis, S. pneumoniae and H. influenzae
Latex Agglutination
Test Suppliers* Product Information
Directigen Becton-Dickinson Microbiology
Systems
Cat # 4950160: N. meningitidis groups A/Y and C/W135 Kit
Cat # 4952260: H influenzae type b Kit
Cat # 4951960: S. pneumoniae Kit
Cat # 4952360: Meningitis Combo Test Kit for N. meningitidis groups C/W135, A/Y, B/E. coli
K1, H. influenzae type b, S. pneumoniae, and group B streptococcus
MicroScan VWR Scientific Cat # B1049-6  ImmunoSCAN Direct: S. pneumoniae Latex Test Kit
Cat # B1049-7 ImmunoSCAN Direct: Meningitis Test Kit for N. meningitidis groups A/C,
Y/W135
Pastorex Sanofi Diagnostics Pasteur Cat # 61701: Pastorex Meningitis Kit for N. meningitidis groups A, B, C, Y, W135, 
H. influenzae type b, S. pneumoniae and group B streptococcus
Slidex bioMérieux Cat # 58 803: Slidex méningite Kit 5 for detection of N. meningitidis groups A, C, B/
E. coli K1, H. influenzae type b, and S. pneumoniae
Wellcogen Murex Diagnostics, Inc. Cat # ZL26: Wellcogen Bacterial Antigen Kit for detection of N. meningitidis groups
A/C/Y/W135, B/E. coli K1, H. influenzae type b, S. pneumoniae
Cat # ZL21: Wellcogen H. influenzae type b and group B streptococcus
Cat # ZL22: Wellcogen S. pneumoniae
Cat # ZL23: Wellcogen N. meningitidis groups A/C/Y/W135
Cat # ZL24: Wellcogen N. meningitidis B/E. coli K1
*For the manufacturers’ addresses and contact numbers, please see section B4.
Co-Agglutination
Test Supplier* Product Information
Phadebact Pharmacia Diagnostics
(US distributor REMEL)
Cat # 60-401: CSF test for N. meningitidis groups A/B/C/Y/W135, H. influenzae type b, S.
pneumoniae, and group B streptococcus; CSF pneumococcus test; CSF Haemophilus test
*For the manufacturers’ addresses and contact numbers, please see section B4.
Serogrouping/Serotyping Antisera
Test Supplier* Product Information
Serogrouping
antisera
Murex Diagnostics, Inc. Cat # ZM 33: Polyvalent set 1 of N. meningitidis agglutinating antisera
Cat # ZM 34: Polyvalent set 2 of N. meningitidis agglutinating antisera
Cat # ZM 37:  N. meningitidis antiserum group A
Cat # ZM 51:  N. meningitidis antiserum group B
Cat # ZM 39:  N. meningitidis antiserum group C
Cat # ZM 44:  N. meningitidis antiserum group W135
Cat # ZM 41:  N. meningitidis antiserum group X
Cat # ZM 42:  N. meningitidis antiserum group Y
Cat # ZM 43:  N. meningitidis antiserum group Z
Serogrouping
antisera
Difco Laboratories Cat # 2228-50-1: N. meningitidis antiserum group A
Cat # 2229-50-0: N. meningitidis antiserum group B
Cat # 2230-50-7: N. meningitidis antiserum group C
Cat # 2253-50-9: N. meningitidis antiserum group W135
Cat # 2880-50-0: N. meningitidis antiserum group X
Cat # 2281-50-9: N. meningitidis antiserum group Y
Cat # 2891-50-7: N. meningitidis antiserum group Z
Cat # 2252-50-5: N. meningitidis antiserum group Z’
Cat # 2232-50-5: Antiserum Poly - polyvalent antiserum for  N. meningitidis A/B/C/D
Cat # 2910-50-4: Antiserum Poly 2 - polyvalent antiserum for  N. meningitidis X/Y/Z
Slidex pneumo-
kit
bio-Mérieux Cat # 58821: S. pneumoniae
Pneumoslide Becton-Dickinson Microbiology
Systems
Cat # 40840: S. pneumoniae
Serotyping
antisera
Difco Laboratories Cat # 2237-50-0: polyvalent H. influenzae antisera
Cat # 2250-50-2: H. influenzae antisera type a
Cat # 2236-50-1: H. influenzae antisera type b
Cat # 2789-50-2: H. influenzae antisera type c
Cat # 2790-50-9: H. influenzae antisera type d
Cat # 2791-50-8: H. influenzae antisera type e
Cat # 2792-50-7: H. influenzae antisera type f
Serotyping
antisera
Murex Diagnostics, Inc. Cat # ZM 20: H. influenzae antisera type a
Cat # ZM 21: H. influenzae antisera type b
Cat # ZM 22: H. influenzae antisera type c
Cat # ZM 23: H. influenzae antisera type d
Cat # ZM 24: H. influenzae antisera type e
Cat # ZM 25: H. influenzae antisera type f
*For the manufacturers’ addresses and contact numbers, please see section B4.
  Note: Slashes (/) indicate polyvalent diagnostic reagents and commas (,) indicate monovalent diagnostic reagents.
B3. Table 7: Control Strains for Quality Assurance Testing of Media and Reagents
Medium Control Organism ATCC No. Expected Results












































































No colour or deep red






Optochin test and bile
solubility test
Streptococcus pneumoniae 49619 Optochin susceptible
Bile soluble
X and V factor
requirements
Haemophilus influenzae 49247 Requires both X and V for
growth




Cockeysville, MD 21030, USA
Phone: (1) 800 638-8663
FAX:  (1) 410 584 81 29
BBL Microbiology Systems (orders through Fisher Scientific Co.)
PO Box 4829
Norcross, GA 30091, USA
Phone: (1) 800 766-7000




Hazelwood, MO 63042-2395, USA
Phone: (1) 314 731-8500
FAX: (1)  314 731-8700
bioMérieux s.a.
69280 Marcy-l’Etoile, France
Phone: (33) 4 78 87 20 00
FAX:   (33) 4 78 87 20 90
Telex:  330967
Carr-Scarborough Microbiologicals, Inc. (orders through Remel)
12076 Santa Fe Trail Dr.
Lenexa, KA 66215, USA
Phone: (1) 800 255-6730 (orders)
      (1) 800 447-3641 (customer service)
FAX: (1) 800 621-8251
Difco Laboratories
PO Box 331058
Detroit, MI 48232-7058, USA
Phone: (1) 800 521-0851
(1) 313 462-8500
FAX: (1) 313 462-8517
Fisher Scientific Co.
PO Box 4829
Norcross, GA 30091, USA
Phone: (1) 800 766-7000
FAX: (1) 800 926-1166
Europe/Middle East/Africa Headquarters
Fisher Scientific Overseas Marketing, Inc.
46 Queen Anne Street
London W1M 9LA, United Kingdom
Phone: (44) 171 935-4440
FAX: (44) 171 935-5758
MicroScan
Travenol Laboratories, Inc.
West Sacramento, CA 95691
Mahwah, NJ 07430, USA
Bellevue, WA 98004, USA
Phone: (1) 800 631-7216
Murex Diagnostics, Inc.
Central Temple Hill
Dartford, Kent DA1 5LR, United Kingdom
Phone: (44) 132 227-7711
FAX:  (44) 132 227-3288
Customer Services Department
3075 Northwoods Circle
Norcross, GA 30071, USA
Phone: (1) 404 662-0660
FAX: (1) 404 447-4989
Oxoid
Oxoid s.a.
6 route de Paisy, B.P. 13
69572 Dardilly Cedex, France
Phone: (33) 4 78 35 17 31
FAX:  (33) 4 78 66 03 76
Unipath Limited
Wade Road
Basingstoke, Hampshire RG24, United Kingdom
Phone: (44) 1256 694 364




Ogdensburg, NY 13669, USA
Phone: (1) 800 567-8378
Pastorex
Sanofi Diagnostics Pasteur
3, Bld Raymond Poincaré - BP 3
92430 Marnes-la-Coquette, France
Phone: (33) 1 47 95 60 00




Distributed in the USA by: Remel Laboratories
Remel Laboratories
12076 Santa Fe Trail Dr.
Lenexa, KA 66215, USA
Phone: (1) 800 255-6730 (orders)
      (1) 800 447-3641 (customer service)
FAX: (1) 800 621-8251
Sigma Chemical Co.
PO Box 14508
St. Louis, MO 63178, USA
Phone: (1) 800 325-3010 (orders)
(1) 800 325-8070 (customer service)
Fancy Road, Poole
Dorset, BH17 7NH, United Kingdom
Phone: (44) 0800 373 731
FAX:  (44) 0800 378 785
Sigma-Aldrich Chimie S.a.r.l.
L’Isle d’Abeau Chesnes
B.P. 701, 38297 St. Quentin Fallavier Cedex, France
Phone:  (33) 05 21 14 08





75640Paris Cedex 13, France
Phone:  (33) 1 46 12 49 12
FAX:  (33) 1 46 54 55 47
Distributed in the USA by: Murex Diagnostics, Inc.
Annex C.  Preparation of Media and Reagents
C1. Quality Control of All Media
Immediately after preparation, each medium should be tested with a reference strain
of N. meningitidis, S. pneumoniae and H. influenzae for proper growth characteristics as
described for each medium. Keep a record of all media preparation or purchase dates and
quality control test results. Note any unusual characteristic such as colour of the medium
or slow growth of test bacteria.
C2. Routine Agar and Broth Media
All agar media can be dispensed into 15x100-mm Petri dishes (15 to 20 ml per dish).
After pouring, leave the plates at room temperature for several hours to prevent excess
condensation from forming on the covers of the dishes. Place the plates and store them in
a plastic bag in an inverted position at 4 •C.
Heart Infusion Agar (HIA) and Trypticase Soy Agar (TSA)
These media are general purpose media used with or without blood for isolating and
cultivating a number of microorganisms. The media should appear straw colored (a
yellowish to gold colouring). HIA and TSA are also used for determining the X- and V-
factor requirements of H. influenzae. Each freshly prepared or purchased batch of HIA or
TSA should be quality control tested by determining the X and V requirements of
H. influenzae. A fresh plate is inoculated with a control strain; X, V, and XV disks should
be placed on the inoculated plate identical to that shown in Figure 23. H. influenzae
should grow only around the XV disk.
(a) Prepare the HIA or TSA according to the instructions on the label of the dehydrated
medium. Prepare the volume needed in flasks. These media should be fully
dissolved with no powder on the walls of the vessel, before autoclaving. Autoclave
at 121 •C for 20 minutes.
(b) Cool to 50 •C and pour into 15x100-mm Petri dishes.
(c) Allow to solidify and condensation to dry out before placing in plastic bags and
storing at 4 •C until used.
Blood Agar Plate (BAP): TSA + 5% Sheep Blood
BAP is used as a general blood agar medium (sheep blood agar plate). It is also used
for the optochin test and subcultures of S. pneumoniae. The plate should appear a bright
red colour. If the plates appear dark red, the blood has been added when the agar was too
hot. If this happens, discard the medium and prepare another batch. Test each new,
freshly prepared or purchased batch of BAP for growth and haemolytic reaction with a
strain of S. pneumoniae. The colonies are small and should appear grey to grey-green
surrounded by a distinct greenish halo in the agar similar to that shown in Figure 12.
(a) Prepare TSA according to the instructions given on the label of the dehydrated
powder. It is convenient to prepare 500 ml of molten agar in a l-litre flask. Add 20 g
of agar into 500 ml of water. Heat to dissolve.
(b) Autoclave at 121 °C for 20 minutes. Cool to 60 •C.
(c) Add 5% sterile, defibrinated sheep blood (25 ml sheep blood is added to 500 ml of
agar). If a different volume of basal medium is prepared, the amount of blood added
must be adjusted accordingly to 5% (e.g. 50 ml of blood per litre of medium).
(d) Dispense 20 ml into 15x100-mm Petri dishes. Allow to solidify, dry out, place in a
plastic bag, and store at 4 •C.
Heart Infusion Rabbit Blood Agar Plate (HIA - Rabbit Blood)
HIA-rabbit blood is used for determining the haemolytic reaction of Haemophilus
species. This medium should appear bright red and look very similar to BAP. If the
medium is dark red, discard and prepare a new batch. Horse blood may be substituted for
rabbit blood in this medium. A strain of H. haemolyticus should be used to quality control
the proper growth and haemolytic reactions of the medium. H. haemolyticus should grow
well and be surrounded by a distinct zone of complete haemolysis which appears as a
clear halo surrounding the colonies.
(a) Prepare the HIA according to the instructions on the label of the dehydrated
medium. Prepare the volume needed in flasks and autoclave at 121 •C for 20
minutes. Cool to 50 •C in a water bath.
(b) Add 5% sterile, defibrinated rabbit blood (5 ml/100 ml of medium) and dispense
into 15x100-mm Petri dishes. Allow to solidify and dry for a few hours. Then, place
in a plastic bag and store at 4 •C.
Horse Blood Agar (Blood Agar Base)
This highly nutritive medium may be used for the primary isolation of H. influenzae
and for the determination of the haemolysis with H. haemolyticus or other bacteria. The
quality control testing of this medium should be the same as that described for HIA-rabbit
blood.
(a) Prepare blood agar base according to the instructions on the label of the dehydrated
medium. Oxoid number 2 base is best, but other blood agar bases may be substituted.
(b) Autoclave at 121 •C for 15 minutes, and cool to 50 •C in a water bath.
(c) Add horse blood (5 ml/100 ml of medium).
(d) Mix well, dispense in 15x100-mm Petri dishes. Allow to solidify and dry out excess
moisture before placing in plastic bags and storing at 4 •C.
Trypticase Soy Broth (TSB)
TSB is used for making suspensions of H. influenzae prior to testing for X- and V-
factor requirements. Heart infusion broth, sterile saline or PBS may be substituted for
TSB. H. influenzae does not grow in TSB but the medium should not be toxic to other
bacteria. Therefore, S. pneumoniae should be used to quality control for toxicity.
Inoculate a tube of medium with a loop of freshly growing strain of S. pneumoniae;
incubate overnight at 35 •C. The broth should be turbid the next day. Subculture the broth
to test for proper growth characteristics of S. pneumoniae (use a BAP).
(a) Prepare the TSB according to the instructions on the label of the dehydrated
medium.
(b) Dispense 5 ml into 15x125-mm tubes, autoclave at 121• C for 20 minutes, cool, and
store at 4 •C.
Blood Culture Broths
Each new batch of freshly prepared or purchased blood culture medium should be
tested for supporting the growth of N. meningitidis, S. pneumoniae and H. influenzae.
Add 1 to 3 ml of sterile rabbit, horse, or human blood to three bottles of freshly prepared
blood culture medium. A fresh culture of each of the three bacteria should be inoculated
into separate blood culture bottles. Make a dilute suspension of growth from an agar plate
in broth by collecting a loopful of the growth and suspending it in 1-2 ml of broth.
Inoculate this suspension into the blood culture broth to be tested. Incubate the broths at
35 •C for 7 days, observe for growth and subculture at 14 hours and 48 hours. All three
bacteria should be recovered on subculture after 14 and 48 hours.
(a) Follow the instructions of the manufacturer on the label of each bottle of dehydrated
TSB.
(b) Add 0.25 g SPS per litre of medium. SPS is especially important for recovery of
H. influenzae.
(c) Dispense in 20-ml (paediatric blood culture bottle) and 50-ml (adult blood culture
bottle) amounts into suitable containers (tubes or bottles) with screw-caps with
rubber diaphragms. The amount of liquid in the containers should make up at least
two-thirds of the total volume of the container.
(d) Sterilize by autoclaving at 121 •C for 15 minutes. Cool and store medium at room
temperature.
C3. Special Media
Chocolate Agar Plate (CAP)
CAP with growth supplements is a medium that supports the special growth
requirements needed for the isolation of fastidious organisms, such as H. influenzae and
N. meningitidis when incubated in a 5% CO
2 atmosphere. CAP has reduced concentration
of agar, which increases the moisture content of the medium.
Supplemented chocolate agar should support the growth of N. meningitidis,
H. influenzae, and S. pneumoniae. Chocolate agar slants for transport and short-term
storage can be prepared in the same manner as that described for agar plates, except that
the medium is dispensed in 16x125-mm screw-cap tubes and slanted before solidifying.
All freshly prepared or purchased chocolate agar media should be tested with the three
species of bacteria to determine the medium’s capacity to support their growth. Chocolate
agar slants should look brown to brownish-red in colour. N. meningitidis and H.
influenzae should appear as a greyish, almost translucent film on the slant’s surface with
no discolouring of the medium after 24 hours of incubation. S. pneumoniae should appear
as small grey to grey-green colonies with a very distinct greenish discolouring of the
medium (see Figures 7 and 12 for these reactions). If the medium does not support the
growth of one or all of the bacteria, discard and prepare or purchase a fresh batch. If H.
influenzae does not grow, the IsoVitaleX or its equivalent may have been inadvertently omitted.
Chocolate Agar with TSA and Growth Supplement
(a) Use TSA as the basal medium. Prepare double strength (20 g in 250 ml distilled
water). Autoclave, and cool to 50 •C. Use the thermometer to verify the cooling
temperature.
(b) Haemoglobin solution: Prepare a solution of 2% haemoglobin (5 g in 250 ml
distilled water). Mix the haemoglobin in 5-6 ml of the distilled water to form a
smooth paste. Continue mixing as the rest of the water is added. Autoclave, and cool
to 50 •C.
(c) Add the haemoglobin solution to the double-strength TSA and continue to hold at 50 •C.
Alternative to steps a-c: If a haemoglobin solution is unavailable, an alternative is
to add 5% sterile defibrinated sheep, rabbit, guinea pig, or horse blood (5 ml blood per
100 ml agar) to full-strength TSA agar base (20 g in 500 ml distilled water). DO NOT use
human blood. After the base medium has been autoclaved and cooled to 50 •C, add the
blood and place in a hot water bath at no more than 80 •C for 15 minutes or until a
chocolate colour is achieved. Then cool to 50 •C.
(d) Supplement: after the haemoglobin solution or the defibrinated blood has been
added to the base medium and the medium has cooled to 50 •C, add growth
supplement (such as IsoVitaleX or Vitox) to a final concentration of 1%. Mix the
ingredients by gently swirling the flask; avoid forming bubbles.
(e) Dispense 15 to 20 ml in each 15x100-mm Petri dish.
Chocolate Agar with Gonococcus Medium (GC) Base and Growth Supplement
(a) Suspend 7.2 g of GC agar base in 100 ml of distilled water. Mix thoroughly, heat with frequent
agitation, and bring to a boil for 1 minute to completely dissolve the powder.
(b) Autoclave the bottle at 121 •C for 15 minutes. Cool to 50 •C.
(c) Add 100 ml of warm distilled water to 2 g of soluble haemoglobin powder. Mix the
powder with 5-10 ml of water until a smooth paste is achieved. Gradually add the
balance of water until the solution is homogenous. Continually stir the solution
during the addition of water. Autoclave the solution at 121 •C for 15 minutes. Cool
to 50 •C. Alternatively, use 100 ml ready-made 2% sterile haemoglobin solution, warmed to 50 •C.
(d) Reconstitute the growth supplement (e.g. IsoVitaleX or Vitox): reconstitute each
lyophilized vial by aseptically transferring with a sterile needle and syringe 10 ml of
the accompanying diluent. Shake to assure complete solution. After reconstitution,
use immediately, or store at 4 •C and use within 2 weeks.
(e) Aseptically add 100 ml sterile haemoglobin solution and growth supplement to 100
ml of GC agar base solution (2 ml of IsoVitaleX or 4 ml of Vitox). Mix gently, but
thoroughly, to avoid air bubbles in agar.
(f). Dispense 15 to 20 ml into sterile 15x100-mm Petri dishes.
(g) Allow the medium to stay at room temperature for several hours. Place plates in a
plastic bag and store at 4 •C.
Cystine Trypticase Agar (CTA) with 1% Carbohydrate (a semi-solid medium)
(a) Suspend 28 g of CTA medium (BBL) or 29.5 g (Difco) in 900 ml of distilled water.
Mix thoroughly, heat with frequent agitation, and bring to a boil for 1 minute to
completely dissolve the powder.
(b) Autoclave the flask at 121 °C for 15 minutes. Cool to 50 °C.
(c) Prepare 10% glucose solution using 10 g glucose in 100 ml of distilled water. Filter
sterilize using a 0.22 micron filter.
(d) Aseptically add this entire solution (100 ml of 10% glucose solution) to the 900 ml
of the CTA medium to obtain a final 1% concentration of the glucose.
(e) Dispense 7 ml in 16 x 125 mm glass tubes with screw caps.
(f) Store at 4 °C.
(g) Repeat this procedure for the remaining 3 carbohydrates: maltose, lactose and
sucrose.
Levinthal’s Medium for Haemophilus spp.
Solution A: Levinthal’s stock solution
(a) Suspend 37 g of brain heart infusion broth base into 450 ml of endotoxin-free water.
Mix thoroughly and heat to boiling to dissolve powder.
(b) Add 50 ml of defibrinated rabbit blood to the hot mixture and mix well.
(c) Cool and filter through gauze or glass wool.
(d) Centrifuge the liquid portion at 12,000 revolutions per minute for 50 minutes.
(e) Filter sterilize, and dispense in 100-ml amounts.
Solution B: agar
(a) Add 7.5 g of agar to 500 ml of endotoxin-free water. Heat to dissolve.
(b) Autoclave at 121 •C for 20 minutes.
The final agar medium is prepared by adding 500 ml of filter sterilized Levinthal’s
solution to 500 ml of sterile agar base at 55 •C. Aseptically dispense into sterile Petri
dishes.
C4. Transport and Storage Media
Trans-Isolate (T-I) Medium
T-I medium is a biphasic medium that is useful for the primary culture of
N. meningitidis, S. pneumoniae, and H. influenzae from CSF and blood samples. It can
be used as a growth medium as well as a holding and transport medium.
(a) Use glass serum bottles with flange-type, slotted rubber plugs and aluminum crimp
seals. Any size from 20- or 30-ml capacity or greater will do, provided that the
combined volume of solid and liquid phases equals approximately one-half the
capacity of the bottle.
Diluent for solid and liquid phases:
a 3- (N-morpholino) propanesulfonic acid (MOPS) buffer
0.1 M, pH 7.2 20.93 g
b Distilled water up to 1000 ml after adjusting to pH 7.2 with NaOH
(b) Solid phase:
Activated charcoal   2.0 g
Soluble starch   2.5 g
Agar (Difco) 10.0 g
Suspend in 500 ml of MOPS buffer and add a magnetic bar to the flask. Heat on a
magnetic stirrer-heater to dissolve the starch and the agar. While stirring to keep the
charcoal in suspension, dispense 5.0 ml to each 20-ml serum bottle. Cap each bottle
with a piece of aluminium foil and autoclave in metal baskets at 121 °C for 20
minutes. Remove from the autoclave and slant the baskets until the bottles cool, so
that the apex of the agar reaches the shoulder of each bottle.
(c) Liquid phase:
Tryptic soy broth (Difco) 30.0 g
Gelatin (Difco) 10.0 g
MOPS buffer           500.0 ml
. Heat the medium to dissolve the gelatin and avoid coagulation. Then autoclave at
121 °C for 15 minutes. To permit use of the medium for blood culture, add
aseptically when cool:
SPS 250.0 mg
Dissolve by mixing vigorously in 5 ml or less of MOPS buffer.
Pass through a 0.22-µ membrane filter to sterilize before adding to the medium.
Optional additive: Ten ml of the growth supplement (Vitox or IsoVitaleX) to help
support growth of H. influenzae can be added aseptically to cooled medium.
Alternatively, add 0.1 ml of the supplement to an individual T-I bottle (l% of the volume
of both phases) or to a limited number of bottles, as needed.
(d) Dispense 5 ml of the broth aseptically into each of the bottles containing the solid-
phase slants. Seal with sterile rubber stoppers and aluminum caps. Use a hand-
crimping tool to fasten the aluminium caps if an automated system is not available.
T-I bottles can be stored and used for at least 2 years if tightly capped and stored at
4 °C. In the refrigerator, the liquid phase becomes gelatinous but re-liquefies at
room temperature. Before use, check several inoculated bottles for their ability to
support meningococcal growth as well as some uninoculated bottles for sterility at
35 °C. Before inoculation, the bottles should be pre-warmed in the incubator (35 °C-
37 °C) or allowed to reach room temperature (25 °C-30 °C).
Greaves solution for preservation of strains by freezing
Albumin, bovine, fraction V  10.0 g
L-glutamic acid, sodium salt (Fluka, Buchs, Switzerland, 49621)  10.0 g
Glycerol  20.0 ml
Distilled water            200.0 ml
Mix all ingredients and let them dissolve for 2-3 hours. Sterile filter the solution. Transfer
the solution to a sterile tube. Incubate for 2 days at 35 °C-37 °C to control the sterility of
the medium. Store at 4 °C.
C5. Miscellaneous Reagents
Reagents for Gram Stain (Hucker Modification)
(a) Ammonium oxalate-crystal violet
Solution a.
Crystal violet (certified)                2.0 g
Dissolve in 95% ethyl alcohol              20.0 ml
Solution b.
Ammonium oxalate    0.8 g
Distilled water  80.0 ml
Mix solutions a. and b. Let stand overnight. Filter through coarse filter paper before
use.
(b) Gram’s iodine (protect solution from light)
Iodine (crystalline)    1.0 g
Potassium    2.0 g
Distilled water            300.0 ml
Grinding the dry chemicals in a mortar with small additions of distilled water may
be helpful in preparing the solution.




Safranin-O (certified)    2.5 g
95% ethyl alcohol            100.0 ml
Working solution:
Safranin stock solution  10.0 ml
Distilled water  90.0 ml
b. Ziehl-Nielsen carbol-fuchsin (considered by many to be a more effective
counter-stain than safranin)
Basic fuchsin    0.3 g
95% ethyl alcohol  10.0 ml
Phenol crystals, melted    5.0 ml
Distilled water  95.0 ml
Dissolve fuchsin in alcohol. Add the 5% phenol solution. Let stand overnight. Filter
through coarse filter paper.
Note: This solution can be used as described or diluted 1:10. Alternatively,
counterstain can be prepared as a 0.3-0.5 aqueous solution of the basic fuchsin.
Gram-stain kits or individual reagents are available commercially from several
laboratory supply companies.
McFarland Turbidity Standards
Prepare a 1% solution of anhydrous BaCl
2 (barium chloride) and a 1% solution of
H2SO4 (sulfuric acid). The McFarland standards consist of mixtures of the two solutions
in various proportions to form a turbid suspension of BaSO4. A 0.5 McFarland standard is
prepared by mixing 0.05 ml of the 1% barium chloride solution with 9.95 ml of 1%
sulfuric acid solution, while 1.0 McFarland standard is prepared by mixing 0.1 ml of the
1% barium chloride solution with 9.9 ml of 1% sulfuric acid solution. The resulting
mixture is placed in a tube identical to that used for preparing the dilution used for the
bile solubility test and the Haemophilus ID plate. The same size tube (screw-capped) and
volume of liquid must be used. Store in the dark at room temperature when not in use.
Prepare a fresh standard solution every 6 months. McFarland standard density solution
will precipitate and clump over time, and it needs vigorous vortexing before each use.
Mark the tube to indicate the level of liquid, and check before use to be sure that
evaporation has not occurred. If it has, prepare a fresh standard.
Skin Antiseptic
Iodine tincture: add 100 ml of 70% isopropyl alcohol to 1 g of iodine.
Annex D. Serotyping of S. pneumoniae
Typing of the pneumococci isolated from patients with various clinical syndromes,
such as sporadic cases of meningitis, is not usually necessary. However, in some studies,
where the study protocols focus on evaluation of vaccine efficacy and transmission of
organisms, it will be necessary to serogroup and serotype the pneumococci. The
checkerboard typing system will sufficiently identify the serotypes of pneumococci in
most cases. There will be studies that will require complete testing for all pneumococcal
types and the isolates will have to be sent to a reference laboratory for identification of all
90 serotypes. The availability of Omniserum (Statens Seruminstitut, Copenhagen, Denmark), a pooled
pneumococcal serum that reacts with all types, provides clinical microbiology
laboratories with an invaluable reagent for rapid identification of pneumococci.
D1. Quellung Typing of S. pneumoniae
A Quellung reaction results when a type-specific antibody is bound to the
pneumococcal capsular polysaccharide and causes a change in the refractive index of the
capsule so that it appears “swollen” and more visible. The pneumococcal cell stains dark
blue and is surrounded by a sharply demarcated halo, which represents the outer edge of
the capsule (Figure 26). The light transmitted through the capsule appears brighter than
either the pneumococcal cell or the background. Single cells, pairs, chains, and even
clumps of cells may have Quellung reactions.
The Quellung reaction is traditionally used for the typing of pneumococci. This is
the method of choice because it is easy, fast, accurate, and economical. Most laboratories
do not type pneumococcal isolates because of the large number of diagnostic antisera
required for typing; a total of 90 different pneumococcal types have been described.
Types that exhibit close serological cross-reactivity are grouped together. Of the 90 types,
58 belong to 20 groups containing from 2 to 4 types (Table 8); a total of 46 different
pneumococcal types or groups are currently known. Monovalent factor sera (rendered
specific by multiple absorptions or by induction of immunological tolerance to cross-
reacting types previous to immunization) for identification of types within groups will not
be discussed in this manual.
In most parts of the world, about 90% of all pneumococcal strains isolated from
blood or CSF belong to one of the 23 different types or groups represented in the 23-
valent pneumococcal vaccine. A total of 7 pooled sera in addition to 21 type or group
sera are needed in order to type or group these strains by the use of the traditional
pneumococcal diagnostic antisera. However, this manual describes a simple
checkerboard typing system, based on 12 pooled sera, intended for typing and/or
grouping most pneumococci isolated from CSF or blood.
Antigen Preparation and Typing
The type and condition of a culture that is received in the laboratory will determine the
procedure used to prepare a suitable cell suspension for observation of the Quellung
reaction.
Performance of the Test
Figure 26.  Quellung reaction for identification of S. pneumoniae.
(a) Inoculate a BAP with an inoculating loop (always using a freshly prepared BAP).
Inoculate about one-third of the plate heavily and streak the remainder of the plate
for isolated colonies. Place the agar plate in a candle-jar or a carbon dioxide
incubator for 18-24 hours at 35 •C.
(b) Using a sterile loop, sweep across the surface of the 18-24 hours plate for inoculum
and prepare a cell suspension equal to a 0.5 McFarland density standard in 0.5 ml of
saline (0.85% sodium chloride). Optimum Quellung can be observed when there are
25 to 50 cells in a microscopic field.
(c) With a loop or a micropipette, dispense equal amounts (5 to 10 µl) of the cell
suspension and pneumococcal pool antiserum on a microscope slide. Add a small
amount (1 loop) of 0.3% aqueous methylene blue and mix.
(d) Cover the mixture with a 22-mm2 coverslip and incubate at room temperature for 30
minutes.
Reading the Test Results
All positive Quellung reactions are shown in Figure 26. Note the clear area around
the dark cell and the area outside the clear area (the capsule) in the dark background.
Non-Reactive Strains
(a) If a Quellung reaction is not observed in one of the pools with the cell suspension
from an agar plate, inoculate a 1.0 ml Todd-Hewitt broth, which has been
supplemented with 2-3 drops of defibrinated sheep blood.
(b) Incubate at 35 •C for 1-3 hours or until the broth above the blood is turbid.
(c) Use one or two loops of the broth culture and test as in steps (c)-(d) above.
(d) If a Quellung reaction is not observed in any of the pools, the identification of the
strain as
S. pneumoniae should be confirmed by re-testing for optochin susceptibility and bile
solubility.
D2. Typing and/or Grouping of Pneumococci
The capsular reaction test is first carried out with, successively, the nine traditional
pools (A to I) until a positive reaction is observed. Ordinarily, typing then proceeds by
testing the strain in question with antisera against those individual types or groups that
are included in the serum pool that gave a positive reaction. However, the checkerboard
method described here proceeds by testing for a positive reaction with the serum pools (P
to T). The type or group is then established from the reaction pattern by the use of a table
with the types and groups entered in a rectangular checkerboard arrangement (Table 8).
Table 8:  Checkerboard System for Typing and/or Grouping of Most Pneumococci Isolated
From Blood or CSFa,b   (From Reference #9)
Existing
Pool
Type or Group with New Pool Non-Vaccine Related
Type or GroupP Q R S T
A 1 18* 4 5 2
B 19* 6* 3 8
C 20 24*, 31, 40
D 9* 11* 16*, 36, 37
E 12* 10* 33* 21, 39
F 17* 22* 27, 32*, 41*
G 13,  28*
Hc 14 23* 15* 29, 34, 35*, 42,  47*
Ic 25, 38, 43, 44, 45, 46, 48
a The five pooled sera P to T are composed in such a way that each of the 21 vaccine-related types
and/or groups reacts both with one of these sera and with one of the seven pooled sera A to F plus
H.
b All 46 types of groups are shown in the table (Nos. 26 and 30 not being in use).  Asterisks indicate
groups containing the following types: 6, 6A and 6B; 7, 7F, 7A, 7B, and 7C; 9, 9A, 9L, 9N, and 9V;
10, 10F and 10A; 11, 11F, 11A, 11B and 11C; 12, 12F and 12A; 15, 15F, 15A, 15B, and 15C; 16,
16F and 16A; 17, 17F and 17A; 18, 18F, 18A, 18B, and 18C; 19, 19F and 19A, 19B, and 19C; 22,
22F and 22A; 23, 23F, 23A, and 23B; 24, 24A, and 24B; 28, 28F and 28A; 32, 32F and 32A; 33,
33F, 33A, 33B, and 33C; 35, 35A, 35B, and 35C; 41, 41F and 41A; 47 and 47A.  Types and/or
groups present in the currently available 23-valent pneumococcal vaccine are indicated by boldface
type.
c Pools G and I do not react with vaccine types and are, therefore, not included in the chessboard
system. 
Annex E. Biotyping of H. influenzae
In the absence of Hib vaccination, H. influenzae isolated from the CSF of a patient
with clinical meningitis will usually be Hib. Most laboratories will conclude their
identification at that stage. However, in certain cases, reference laboratories may want to
carry out the biotyping of H. influenzae. Biotyping can be performed irrespective of
whether or not a serotype antigen was detected. The biotype is determined by the testing
for indole, ornithine decarboxylase, and urease.
(a) Spot indole test: Transfer a heavy inoculum (a 25-µl loopful) to a piece of filter
paper so that the bacteria are contained in a heavy spot. Add one drop of indole
reagent (Kovac’s reagent) to the cells. A blue colour will appear within 1 minute
when the bacteria are producing indole. A red, pink or pinkish-yellow reaction is
negative.
Do not read the test after 5 minutes, as all reactions may appear positive.
(b) Ornithine decarboxylase test: Inoculate a tube of ornithine medium with a loopful of
bacterial suspension (0.5 McFairland). This suspension can also be used to inoculate
the Haemophilus ID medium described above. After inoculating the ID medium,
cover the ornithine decarboxylase test tube media with sterile mineral oil. Incubate 4
hours or overnight at 35 •C. A purple colour is positive for the presence of the
ornithine decarboxylase enzyme, and a yellow colour or no colour is negative.
(c) Urease test: Inoculate a tube of Christensen’s medium with a loopful of bacteria.
Incubate 4 hours or overnight at 35 •C. A pink to red colour is positive, and no
change or a yellow colour is negative.
(d) The biotype is determined by matching the observed reactions to those described in
Table 9.
Note: When performing these tests follow the specific instructions provided by the
manufacturers as different colour indicators may be employed by different
manufacturers.
Table 9:  Identification of H. influenzae Biotypes
Test Biotype
    I II III IV V VI VII VIII
Urease + + + + - - - -
Indole + + - - + - + -
Ornithine + - - + + + - -
XI. List of Figures
  1. Kit for the collection of CSF.
  2. Collection of  CSF by lumbar puncture.
A. The patient lies on his side with knee flexed and back arched to separate the
lumbar vertebrae. The patient is surgically draped, and an area overlaying the
lumbar spine is disinfected.
B. The space between lumbar vertebrae L3 and L4 is palpated with the sterilely
gloved forefinger.
C. The spinal needle is carefully directed between the spinous processes, through
the intraspinous ligaments into the spinal canal.
  3. Collection of blood from an arm.
1. Apply the tourniquet.
2. Select a vein.
3. Plan proposed puncture site.
  4. Processing of CSF.
  5. Trans-Isolate medium everywhere.
  6. N. meningitidis -- proper streaking and growth on blood agar plate.
  7. S. pneumoniae -- proper streaking and growth on blood agar plate.
  8. H. influenzae -- proper streaking and growth on chocolate agar plate.
  9. Gram stain of CSF:
a  N. meningitidis: intra-cellular, Gram-negative diplococci,
b  S. pneumoniae: Gram-positive diplococci, and
c  H. influenzae: Gram-negative pleomorphic coccobacilli.
10. On chocolate agar plate, H. influenzae appear as large colourless to grey opaque
colonies with no discoloration of the surrounding medium.
11. Overnight growth of N. meningitidis on blood agar plate appears as round, moist,
glistening and convex colonies.
12. S. pneumoniae appear as small greyish mucoid (watery) colonies with a greenish
zone of alpha-haemolysis surrounding them on the blood agar plate.
13. Presumptive identification of N. meningitidis, S. pneumoniae, and H. influenzae.
14 N. meningitidis (left), S. pneumoniae (right), and H. influenzae (top):
(a) growth on blood agar plate and (b) growth on chocolate agar plate.
15. Identification of N. meningitidis.
16. Kovac’s oxidase test -- positive reaction.
17. Agglutination, with clearing of the liquid, occurs when a suspension of the isolate
is mixed with its homologous antiserum (left). A negative reaction, as in the case
of heterologous antiserum (centre) and with saline (right), remains smooth and
turbid.
18. Cystine trypticase agar-sugar reactions differentiating N. meningitidis from other
Neisseria species. Acid production (yellow colour) shows oxidative utilization of
dextrose and maltose with no utilization of lactose and sucrose.
19. Identification of S. pneumoniae.
20. Optochin susceptibility test for identification of S. pneumoniae. The strain in the
top streak is resistant to optochin and, therefore, is not a pneumococcus. The
strains in the centre and lower streaks are susceptible to optochin and appear to be
pneumococci.
21. The bile solubility test for two different strains. Strain 1 is not S. pneumoniae as
both tubes are turbid. There is a slight decrease in turbidity in the tube containing
bile salts for strain 1 (2nd tube from the left) but the tube is almost as turbid as the
control tube (1st tube on the left). Strain 2 is S. pneumoniae. Note that the tube on
the far right is clear, all the turbidity due to the cells has disappeared and the cells
have lysed; by contrast the control tube (3rd tube from the left) is still very turbid.
22. Identification of H. influenzae.
23. Growth factor requirements. H. influenzae will grow only around the disk
containing both X and V factors.
24. Growth factor requirements for H. influenzae: Haemophilus quad ID plate. This
agar plate is divided into four compartments. One quadrant includes medium
containing haemin (X factor) (upper left). One quadrant includes medium
containing nicotinamide dinucleotide (V factor) (lower left). Another quadrant
contains medium that includes both X and V factors (upper right). The fourth
quadrant contains heart infusion agar with 5% horse blood (lower right).
25. Instructions for using silica gel packages for transport of isolates.
26. Quellung reaction for identification of S. pneumoniae.
XII. Abbreviations
ATCC American type culture collection
BAP Blood agar plate
CAP Chocolate agar plate
CDC Centers for Disease Control and Prevention
CSF Cerebrospinal fluid
GC Gonococcus medium
HIA Heart infusion agar
HIA-rabbit blood Heart infusion rabbit blood agar plate
Hib Haemophilus influenzae type b
MOPS 3- (N-morpholino) propanesulfonic acid
NAD Nicotinamide adenine dinucleotide
O/N Overnight
PBS Phosphate-buffered saline
rpm revolutions per minute
SPS Sodium polyanetholesulfonate
T-I Trans-Isolate medium
TSA Trypticase soy agar
TSB Trypticase soy broth
WHO World Health Organization
